Taysha Gene Therapies, Inc. short interest in 2026
In 2026, Taysha Gene Therapies, Inc.'s disclosed short interest ran from 20.75% of shares outstanding on 15 Jan 2026 to 15.78% on 15 Sep 2026, a change of -4.97 percentage points. The year's high was 20.75% on 15 Jan 2026 and its low 12.54% on 29 May 2026, averaging 15.64% across 17 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 23.57 days on 27 Feb 2026. Full history: Taysha Gene Therapies, Inc..
Cite this page
By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2026 in figures
- Start of year
- 20.75% (15 Jan 2026)
- End of year
- 15.78% (15 Sep 2026)
- Change
- -4.97 pp
- High
- 20.75% (15 Jan 2026)
- Low
- 12.54% (29 May 2026)
- Average
- 15.64%
- Highest days to cover
- 23.57 (27 Feb 2026)
- SEC filings marked
- 6
Every report in 2026
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2026 | 20.75% | 20.13 | |
| 30 Jan 2026 | 20.33% | 20.49 | |
| 13 Feb 2026 | 17.87% | 21.59 | |
| 27 Feb 2026 | 18.14% | 23.57 | |
| 13 Mar 2026 | 16.94% | 15.86 | |
| 31 Mar 2026 | 14.72% | 13.08 | 10-K filed, results (8-K) |
| 15 Apr 2026 | 13.55% | 14.24 | |
| 30 Apr 2026 | 13.94% | 14.00 | |
| 15 May 2026 | 12.78% | 15.09 | 10-Q filed, results (8-K) |
| 29 May 2026 | 12.54% | 16.37 | |
| 15 Jun 2026 | 13.48% | 15.38 | |
| 30 Jun 2026 | 14.41% | 8.06 | |
| 15 Jul 2026 | 15.77% | 13.34 | |
| 31 Jul 2026 | 16.25% | 19.00 | |
| 14 Aug 2026 | 14.34% | 17.42 | 10-Q filed, results (8-K) |
| 31 Aug 2026 | 14.36% | 19.40 | |
| 15 Sep 2026 | 15.78% | 18.78 |
See also: Taysha Gene Therapies, Inc.'s full history · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.